{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:43:51Z","timestamp":1785519831691,"version":"3.56.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10620-025-08857-8","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:24:32Z","timestamp":1739993072000},"page":"1283-1285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PPIs Have It: Does Tegoprazan Affect Gastric Emptying and Produce Dyspeptic Symptoms?"],"prefix":"10.1007","volume":"70","author":[{"given":"Jos\u00e9 Mar\u00eda","family":"Remes-Troche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"8857_CR1","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s10620-009-1076-x","volume":"55","author":"M Sanaka","year":"2010","unstructured":"Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci. 2010;55:2431\u20132440. https:\/\/doi.org\/10.1007\/s10620-009-1076-x.","journal-title":"Dig Dis Sci."},{"key":"8857_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.22037\/ghfbb.v16i1.2652","volume":"16","author":"R Beas","year":"2023","unstructured":"Beas R, Riva-Moscoso A, Montalvan-Sanchez E et al. Prevalence of small intestinal bacterial overgrowth in patients with gastroparesis: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2023;16:438\u2013447. https:\/\/doi.org\/10.22037\/ghfbb.v16i1.2652.","journal-title":"Gastroenterol Hepatol Bed Bench."},{"key":"8857_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10620-023-08162-2","volume":"69","author":"C Dur\u00e1n-Rosas","year":"2024","unstructured":"Dur\u00e1n-Rosas C, Priego-Parra BA, Morel-Cerda E et al. Incidence of small intestinal bacterial overgrowth and symptoms after 7 days of proton pump inhibitor use: a study on healthy volunteers. Dig Dis Sci. 2024;69:209\u2013215. https:\/\/doi.org\/10.1007\/s10620-023-08162-2.","journal-title":"Dig Dis Sci."},{"key":"8857_CR4","doi-asserted-by":"publisher","unstructured":"Lim, H.S., Yoon, Hj., Jung, HK. et al. Effects of tegoprazan, potassium-competitive acid blocker, on the gastric emptying and postprandial symptoms in healthy humans. Dig Dis Sci. (2024). https:\/\/doi.org\/10.1007\/s10620-024-08714-0","DOI":"10.1007\/s10620-024-08714-0"},{"key":"8857_CR5","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/s41395-018-0264-8","volume":"113","author":"T Oshima","year":"2018","unstructured":"Oshima T, Miwa H. Functional dyspepsia\u2014a revolution in management. Am J Gastroenterol. 2018;113:1420\u20131422. https:\/\/doi.org\/10.1038\/s41395-018-0264-8.","journal-title":"Am J Gastroenterol."},{"key":"8857_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1365-2036.2007","volume":"26","author":"H Miwa","year":"2007","unstructured":"Miwa H, Nakajima K, Yamaguchi K et al. Generation of dyspeptic symptoms by direct acid infusion into the stomach of healthy Japanese subjects. Aliment Pharmacol Ther. 2007;26:257\u2013264. https:\/\/doi.org\/10.1111\/j.1365-2036.2007.","journal-title":"Aliment Pharmacol Ther."},{"key":"8857_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00535-021-01801-3","volume":"56","author":"K Ota","year":"2021","unstructured":"Ota K, Takeuchi T, Kojima Y et al. Administration of a standard dose of vonoprazan fumarate delays gastric emptying in Japanese healthy adults: a prospective clinical trial. J Gastroenterol. 2021;56:722\u2013731. https:\/\/doi.org\/10.1007\/s00535-021-01801-3.","journal-title":"J Gastroenterol."},{"key":"8857_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.15403\/jgld-4837","volume":"32","author":"S Shinozaki","year":"2023","unstructured":"Shinozaki S, Osawa H, Hayashi Y et al. Vonoprazan therapy is as effective for functional dyspepsia without heartburn as acotiamide therapy. J Gastrointestin Liver Dis. 2023;32:23\u201329. https:\/\/doi.org\/10.15403\/jgld-4837.","journal-title":"J Gastrointestin Liver Dis."},{"key":"8857_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1124\/jpet.117.244202","volume":"364","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Take Y. Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther 2018;364:275\u2013286.","journal-title":"J Pharmacol Exp Ther"},{"key":"8857_CR10","doi-asserted-by":"publisher","first-page":"313","DOI":"10.5056\/jnm23150","volume":"30","author":"CW Huh","year":"2024","unstructured":"Huh CW, Youn YH, Jung DH et al. Efficacy of tegoprazan in patients with functional dyspepsia: a prospective, multicenter, single-arm study. J Neurogastroenterol Motil. 2024;30:313\u2013321. https:\/\/doi.org\/10.5056\/jnm23150.","journal-title":"J Neurogastroenterol Motil."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08857-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-08857-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08857-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T01:48:30Z","timestamp":1743904110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-08857-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["8857"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-08857-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"29 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"J.M. Remes-Troche is an adviser and advisory council member for Asofarma, Carnot, PRO.MED.CS Praha a.s., and Pisa. He is a speaker for Asofarma, Abbot, Carnot, Chinoin, Ferrer, Johnson and Johnson, Medix, and Medtronic.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}